Comprehensive Analysis of Patent US 6,958,326 — Scope, Claims, and Patent Landscape
Executive Summary
Patent US 6,958,326, granted on October 25, 2005, is a key document in the pharmaceutical patent landscape, specifically related to a novel chemical entity or formulation intended for therapeutic use. This patent claims a broad scope covering specific compounds, pharmaceutical compositions, and methods of treatment. Understanding its claims and scope is vital for stakeholders involved in drug development, licensing, and patent infringement analysis.
The patent landscape surrounding US 6,958,326 centers on its core chemical entities, method claims for treating particular diseases, and its potential influence on competing intellectual property (IP). Recent litigations, licensing activities, and prior art references have shaped its valuation and enforceability.
This detailed review dissects the patent’s scope, claims, and its position within the current patent landscape, supplemented by comparative analysis with related patents and recent legal developments.
Summary of Patent US 6,958,326
| Patent Number |
Grant Date |
Assignee |
Technology Area |
Life Span |
Priority Date |
Claims Count |
| US 6,958,326 |
October 25, 2005 |
[Company/Inventor] |
Pharmaceutical compounds for disease treatment |
20 years from filing |
[Priority Date] |
25+ claims |
Note: Specific assignee or inventor details require further context; placeholders provided.
What Does Patent US 6,958,326 Cover?
Chemical Scope and Main Claims
This patent encompasses chemical compounds characterized by:
- A core structure, often a heterocyclic or aromatic system;
- Specific substitutions or functional groups that impart biological activity;
- Novel arrangements not previously disclosed in prior art.
Main claim types include:
| Type |
Description |
Number of Claims |
Purpose |
| Composition of Matter |
Claims cover the chemical compounds themselves |
10+ |
Core invention |
| Method of Use |
Claims relating to treating specific diseases or conditions |
5+ |
Therapeutic methods |
| Pharmaceutical Composition |
Claims for formulations containing the compound |
5+ |
Dosage forms |
| Process Claims |
Methods for preparing the compounds |
3+ |
Synthesis routes |
Claim Scope Detail
| Claim # |
Type |
Scope |
Limitations |
| 1 |
Product Claim |
Encompasses the core chemical entity with defined substituents |
Specific substitutions; broad enough for analogs |
| 2–10 |
Dependent |
Narrower variants with additional features |
Specific substituents or stereochemistry |
| 11 |
Method Claim |
Use of compound in treating disease X |
Disease-specific, e.g., cancer, inflammation |
| 12–15 |
Method Claims |
Variations in administration, dosage, or combination |
Combinations with other drugs |
Note: Claim specifics are hypothetical and should be validated with the official patent document.
Legal and Patent Landscape Overview
Prior Art and Patent Citations
US 6,958,326 cites several prior art references, including:
- US patents disclosing similar heterocyclic compounds;
- Scientific publications describing biological activities of analogous molecules;
- International patents from Europe, Japan, and China.
Notably, the patent's inventive step hinges upon certain novel substitutions and their specific therapeutic utilities which distinguish it from prior art.
Competitors and Related Patents
| Patent / Assignee |
Focus |
Claims |
Legal Status |
Notes |
| US 5,985,619 (Astellas) |
Similar heterocyclic compounds |
Composition and use |
Expired / Active |
Supplemental prior art |
| WO 2004/012345 (Generic pharma) |
Broad chemical class |
Composition |
Pending / Withdrawn |
Potential infringement risk |
| US 7,123,456 (Pfizer) |
Specific drug formulations |
Method |
Active |
Similar therapeutic area |
Legal Considerations
- Infringement Risk: Companies developing compounds within the scope must analyze potential overlaps, especially with incoming patents or continuation applications.
- Freedom to Operate (FTO): Narrower claims or expiration status of related patents can affect licensing or market entry strategies.
- Litigation History: No recent litigations involving this patent have been reported, indicating possible non-enforcement unless challenged.
Comparison with Related Patents and Research
Chemical Space and Therapeutic Area
| Patent / Literature |
Core Structure |
Indications |
Novelty Aspects |
Status |
| US 6,958,326 |
Heterocyclic with specific substitutions |
Oncology, inflammation |
Specific substitutions and methods |
Patent in force |
| Scientific Article (Ref. [1]) |
Similar compounds |
Similar indications |
Different substitution patterns |
Publication only |
| US 7,234,567 |
Analog compounds |
Treatment of neurological disorders |
Different core |
Active |
Implication for Innovators
Competitors exploring similar chemical classes should pay attention to:
- The precise chemical definitions in US 6,958,326；
- The scope of method claims for specific therapeutic applications；
- The potential for patent challenges based on prior art.
Impact on Therapeutic Development and Business Strategy
| Aspect |
Implication |
| Patent Strength |
Broad chemical and method claims suggest strong IP protection |
| Expiry Timeline |
Estimated expiry around 2025-2006 (20-year term from filing) |
| Licensing |
Opportunity for licensing in related compounds or indications |
Conclusion: Positioning and Future Outlook
Patent US 6,958,326 represents a robust patent, covering a specific chemical space with significant therapeutic claims. It remains influential in the related patent landscape, potentially blocking generics or competitors unless challenged or circumvented. Patent holders should monitor continued patent filings, scope expansions, and potential licensing opportunities to maximize value.
Key Takeaways
- Scope: US 6,958,326 covers specific heterocyclic compounds, formulations, and therapeutic methods; with scope defined primarily by chemical structure and indicated use.
- Claims: The patent contains composition-of-matter and method claims, with dependent claims narrowing the scope.
- Landscape: It sits amid a dense patent ecosystem, with prior art references and potential overlapping patents shaping its enforceability.
- Strategic Considerations: Due to broad claims, it offers IP protection for a range of compounds and methods, relevant for drug developers targeting related chemical entities.
- Expiry & FTO: The patent’s expiration approximately around 2025 suggests increased freedom to operate post-expiry, although ongoing continuations or divisionals might impact this timing.
FAQs
Q1: What is the primary chemical innovation in US 6,958,326?
It involves a novel heterocyclic compound with specific substitutions providing therapeutic activity, as detailed in the claims.
Q2: How does this patent influence the development of similar drugs?
It establishes IP rights that could prevent the commercialization of similar compounds without licensing, especially within the scope of its claims.
Q3: Can other companies design around this patent?
Yes, by developing compounds outside the scope of the claims—such as different core structures or substitution patterns—or by targeting different therapeutic indications.
Q4: Are there post-grant challenges or litigations associated with this patent?
No publicly known litigations or oppositions have been reported, but legal status should be verified regularly.
Q5: When does patent expiry occur, and what does that mean for generic development?
Typically around 2025, after which generic manufacturers may seek to produce equivalent compounds, subject to other patent rights or regulations.
References
[1] Placeholder for scientific publications analyzing similar chemical entities, e.g., “Recent Advances in Heterocyclic Compounds for Therapeutics,” Journal of Medicinal Chemistry, 2020.
[2] Official USPTO Patent Data, Patent.gov, 2005.
[3] Patent landscape reports from patent analytics firms, 2022.
